Thoratec Corporation

Skip to content

Overview

Webcast ImageWebcast
Q1 2014 Thoratec Corporation Earnings Conference Call (Live)
05/06/14 at 1:30 p.m. PT
THOR (Common Stock)
Price33.68Change+ 0.89
Volume786,400% Change2.71%
04/15/2014 4:00 p.m. ETPricing delayed 20 minutes

Thoratec is the world leader in mechanical circulatory support with the broadest product portfolio to treat the full range of clinical needs for patients suffering from advanced heart failure. The company's products include the HeartMate LVAS and Thoratec VAD, with more than 20,000 devices implanted in patients suffering from heart failure. Thoratec also manufactures and distributes the CentriMag and PediMag / PediVAS product lines. Thoratec is headquartered in Pleasanton, California. For more information, visit www.thoratec.com.

Recent News

More >>
DateTitle 
04/14/14Thoratec Schedules First Quarter Conference Call, Webcast
PLEASANTON, Calif., April 14, 2014 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today announced that it will report its operating results for the first quarter of fiscal year 2014 on Tuesday, May 6. The company will hold a conference call to discuss its financial results and operating activities, open to all interested parties, at 1:30 p.m., Pacific Daylight Time (4:30 ... 
Printer Friendly Version
02/26/14Thoratec Announces Presentations At Investor Conferences For March 2014
PLEASANTON, Calif., Feb. 26, 2014 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today it will be participating in two upcoming investor conferences. On Monday, March 3, the company will participate in the Raymond James 35th Annual Institutional Investors Conference. Taylor C. Harris, Vice President and Chief Financial Officer, will provide an update on the company, ... 
Printer Friendly Version
02/04/14Thoratec® Reports Fourth Quarter 2013 Results
- Revenue of $128.2 million for the fourth quarter of 2013 - GAAP net income per diluted share of $0.23, and non-GAAP net income per diluted share of $0.38 - Company establishes 2014 guidance for revenue of $520 million to $535 million and net income per diluted share of $1.28-1.38 on a GAAP basis and $1.72-1.82 on a non-GAAP basis PLEASANTON, Calif., Feb. 4, 2014 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory sup... 
Printer Friendly Version

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.